Summary of Medicenna Therapeutics Conference Call Company Overview - Medicenna Therapeutics is a clinical stage immunotherapy company focused on developing therapies for oncology, particularly through its proprietary "evolutionary superkinds" licensed from Stanford University [2][3] - The company is listed on TSX and OTCQX, with a market capitalization of approximately CAD 80 million [14] Core Programs and Developments - **Lead Program: MDNA-11** - MDNA-11 is an IL-2 superagonist engineered to target cancer-fighting immune cells, showing response rates of 30-50% in patients who previously failed treatments like Keytruda and Opdivo [3][8] - The drug has been designed to be safer and more potent than other IL-2 therapies, with a focus on reducing administration frequency to every two to three weeks [6][7] - Nearly 100 patients have been treated, with promising data indicating good response rates [7][8] - **Second Program: Bispecific Molecule** - A bispecific molecule combining MDNA-11 with a checkpoint inhibitor (like Keytruda) is planned to enter clinical trials next year [3][4] - This aims to treat patients resistant to existing checkpoint inhibitors [4] - **Third Program: Bezoxifas** - This program is ready for phase three clinical trials, targeting patients who have failed surgery, radiation, and chemotherapy, with phase 2b trials showing survival improvement from 7 months to 14 months [4][13] - The company is actively seeking partnerships for this program [4] Market Opportunity - The potential market for MDNA-11 includes over 100,000 patients annually in the US who have failed checkpoint inhibitors and have no other treatment options [9][10] - The company is focusing on melanoma patients and biomarker-driven populations (MSI high and TMB high) for potential phase two registration trials [10] Future Expectations - Upcoming data readouts for MDNA-11 are expected by the end of the year, including results from melanoma and biomarker-driven patients [10][13] - The company plans to advance the MDNA-113 program towards IND enabling studies, leading to phase one and two clinical trials in the second half of next year [13] Financial Position - Medicenna has CAD 21 million in cash, sufficient to fund operations into Q3 of the following year [14] - Insider ownership stands at approximately 22% [14] Analyst Coverage - The company is covered by several analysts from firms including Bloom Burton, Jones Research, HC Wainwright, and Research Capital [14]